Table 1 Clinicopathological implication of sST2 levels in ER-positive breast cancers
From: Serum soluble ST2 is associated with ER-positive breast cancer
Parameter | N (total = 103) | sST2-2(pg/ml) | |
|---|---|---|---|
Mean ± SEM | p-value | ||
Age (years) | |||
<50 years old | 45 | 75.7 ± 6.6 | <0.0001* |
≥50 years old | 58 | 125.2 ± 7.9 | |
Histological type | |||
IBC | 91 | 108.1 ± 6.3 | 0.0307* |
DCIS | 12 | 69.0 ± 11.5 | |
Stage | |||
0 | 12 | 69.0 ± 11.5 | 0.0108* |
I | 27 | 96.5 ± 11.8 | - |
II | 49 | 112.4 ± 9.0 | - |
III | 15 | 115.0 ± 11.8 | |
Tumor size (cm) | |||
Tis | 12 | 69.0 ± 11.5 | 0.0165* |
T1(≤2) | 37 | 96.9 ± 9.2 | - |
T2 (>2, ≤5) | 50 | 116.8 ± 9.1 | |
T3 (>5) | 4 | 123.5 ± 8.6 | - |
Lymphonodus status | |||
Positive | 70 | 97.3 ± 7.2 | 0.0119 |
Negative | 33 | 116.8 ± 9.6 | |
PR status | |||
Positive | 99 | 102.6 ± 6.0 | 0.4439 |
Negative | 4 | 125.9 ± 16.6 | |
Tissue Her-2 | |||
Positive | 10 | 109.9 ± 13.5 | 0.7252 |
Negative | 93 | 102.9 ± 6.3 | |
Ki67 status | |||
>14%(+) | 74 | 120.5 ± 6.6 | <0.0001* |
≤14% (+) | 29 | 60.4 ± 7.7 | |